Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors. Silverstein J, Wright F, Wang M, Young A, et al. Oncologist 2023;28:e950-e959.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Silverstein J, Wright F, Wang M, Young A, et al. Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors. Oncologist 2023;28:e950-e959.
PMID: 37335906